Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China

NCT01947309 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01947309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01947309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China
Lead sponsor
Celgene
Phase
Observational
Overall status
Terminated
Start date
November 30, 2013
Completion date
September 30, 2016
Enrollment
176 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma